CD8A and urinary bladder neoplasm: Finally, in C57BL/6 mice bearing s.c. MB49 bladder tumors, the antitumor effects of avelumab were, once again, abrogated, this time in C57BL/6 mice depleted of CD4+ or CD8+ T cells (Figure 2E).